ReviewFrontiers in immunology2017
Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 58 citations in OpenAlex.
- Inflammatory monocytes constrain YAP-induced cell proliferation.Science advances · 2026Article
- The role of persistent inflammation in failed recovery after perinatal brain injury: is resolution the cure?Journal of neuroinflammation · 2026Review
- T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.Frontiers in immunology · 2026Review
- Review
- Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.Biomolecules · 2025Review
- Melanoma causes phenotypic modulations and metabolic switches of iNKT cells influencing clinical outcomes.Frontiers in immunology · 2025Article
- Article
- Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide.RSC medicinal chemistry · 2024Article
- Dysfunctional states of unconventional T-cell subsets in cancer.Journal of leukocyte biology · 2024Article
- Targeting adrenergic receptors to mitigate invariant natural killer T cells-induced acute liver injury.iScience · 2023Article
- Article
- Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells.JCI insight · 2023Article
- Article
- METTL14-dependent mCell reports · 2022Article
- Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.Frontiers in medicine · 2022Review
- A humanized mouse model forFrontiers in immunology · 2022Article
- Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.Cellular & molecular immunology · 2021Review
- Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.Cancer research · 2021Article
- Invariant natural killer T cells balance B cell immunity.Immunological reviews · 2021Review
- Methods for Studying Mouse and Human Invariant Natural Killer T Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Invariant natural killer T (iNKT) cells are a distinct subset of innate-like lymphocytes bearing an invariant T-cell receptor, through which they recognize lipid antigens presented by monomorphic CD1d molecules. Upon activation, iNKT cells are capable of not only having a direct effector function but also transactivating NK cells, maturing dendritic cells, and activating B cells, through secretion of several cytokines and cognate TCR-CD1d interaction. Endowed with the ability to orchestrate an all-encompassing immune response, iNKT cells are critical in shaping immune responses against pathogens and cancer cells. In this review, we examine the critical role of iNKT cells in antitumor responses from two perspectives: (i) how iNKT cells potentiate antitumor immunity and (ii) how CD1d
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.